BSE Live
Nov 14, 16:01Prev. Close
2547.80
Open Price
2540.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 14, 15:55Prev. Close
2549.00
Open Price
2540.00
Bid Price (Qty.)
2523.20 (5)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Ajanta Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 25.07 | 25.27 | 25.27 | 17.17 | 17.39 | |
| Total Share Capital | 25.07 | 25.27 | 25.27 | 17.17 | 17.39 | |
| Reserves and Surplus | 3,600.24 | 3,382.65 | 3,220.84 | 3,152.01 | 2,867.59 | |
| Total Reserves and Surplus | 3,600.24 | 3,382.65 | 3,220.84 | 3,152.01 | 2,867.59 | |
| Total Shareholders Funds | 3,625.31 | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 110.51 | 108.50 | 97.72 | 101.87 | 92.17 | |
| Other Long Term Liabilities | 27.44 | 26.13 | 28.63 | 20.42 | 20.89 | |
| Long Term Provisions | 80.27 | 39.54 | 24.15 | 19.32 | 17.93 | |
| Total Non-Current Liabilities | 218.22 | 174.17 | 150.50 | 141.61 | 130.99 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 366.27 | 383.74 | 353.02 | 274.37 | 317.20 | |
| Other Current Liabilities | 321.10 | 228.20 | 540.80 | 184.53 | 187.18 | |
| Short Term Provisions | 23.35 | 17.76 | 14.02 | 10.80 | 11.71 | |
| Total Current Liabilities | 710.72 | 629.70 | 907.84 | 469.70 | 516.09 | |
| Total Capital And Liabilities | 4,554.25 | 4,217.44 | 4,304.79 | 3,780.49 | 3,532.06 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,696.65 | 1,452.28 | 1,479.13 | 1,478.09 | 1,502.37 | |
| Intangible Assets | 45.31 | 12.61 | 4.88 | 5.82 | 7.52 | |
| Capital Work-In-Progress | 176.27 | 256.45 | 209.47 | 152.86 | 108.19 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 8.41 | 8.90 | |
| Fixed Assets | 1,918.23 | 1,721.34 | 1,693.48 | 1,645.18 | 1,626.98 | |
| Non-Current Investments | 43.13 | 37.09 | 42.99 | 42.99 | 17.89 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 6.25 | |
| Other Non-Current Assets | 16.83 | 17.34 | 17.13 | 35.31 | 44.73 | |
| Total Non-Current Assets | 1,978.19 | 1,775.77 | 1,753.60 | 1,723.48 | 1,695.85 | |
| CURRENT ASSETS | ||||||
| Current Investments | 438.71 | 330.05 | 510.27 | 121.86 | 138.99 | |
| Inventories | 739.29 | 677.79 | 683.77 | 635.11 | 634.22 | |
| Trade Receivables | 1,225.81 | 1,207.67 | 977.63 | 1,043.62 | 782.30 | |
| Cash And Cash Equivalents | 49.72 | 63.06 | 269.92 | 145.25 | 151.98 | |
| Short Term Loans And Advances | 2.54 | 15.40 | 17.01 | 6.14 | 5.74 | |
| OtherCurrentAssets | 119.99 | 147.70 | 92.59 | 105.03 | 122.98 | |
| Total Current Assets | 2,576.06 | 2,441.67 | 2,551.19 | 2,057.01 | 1,836.21 | |
| Total Assets | 4,554.25 | 4,217.44 | 4,304.79 | 3,780.49 | 3,532.06 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 144.28 | 161.39 | 91.52 | 76.44 | 168.98 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 487.20 | 398.83 | 429.31 | 366.23 | 231.45 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | 2,871.82 | 2,386.47 | 2,242.02 | 1,867.82 | 1,809.65 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 15.50 | 15.63 | 15.63 | 7.09 | 7.09 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 43.13 | 37.09 | 42.99 | 42.99 | 17.89 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 428.59 | 299.15 | 386.06 | 121.86 | 138.99 | |
| Current Investments Unquoted Book Value | 10.12 | 30.90 | 124.21 | -- | -- |
11.11.2025
10.11.2025
Ajanta Pharma Standalone September 2025 Net Sales at Rs 1,220.24 crore, up 8.09% Y-o-Y
04.11.2025
04.11.2025
Ajanta Pharma Consolidated September 2025 Net Sales at Rs 1,353.73 crore, up 14.08% Y-o-Y
10.11.2025
Ajanta Pharma Standalone September 2025 Net Sales at Rs 1,220.24 crore, up 8.09% Y-o-Y
04.11.2025
Ajanta Pharma Consolidated September 2025 Net Sales at Rs 1,353.73 crore, up 14.08% Y-o-Y
29.07.2025
Ajanta Pharma Consolidated June 2025 Net Sales at Rs 1,302.65 crore, up 13.78% Y-o-Y
29.07.2025
Ajanta Pharma Standalone June 2025 Net Sales at Rs 1,208.56 crore, up 12.19% Y-o-Y
12.07.2023
Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang
13.07.2022
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
11.01.2019
Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct
12.10.2018
Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct